|View printer-friendly version|
|BrainStorm Announces Grant of a New European Patent for NurOwn®|
The allowed claims cover methods of treating amyotrophic lateral sclerosis (ALS) using mesenchymal stem cells that secrete neurotrophic factors, including Brain derived neurotrophic factor (BDNF).
"We continue to protect our technology through strategic intellectual property achievements and this Grant from the European Patent Office is a welcome addition to our IP portfolio," commented BrainStorm's CEO Chaim Lebovits. "Having a EU patented product should increase our ability to enter into new commercial partnerships for NurOwn® in
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-announces-grant-of-a-new-european-patent-for-nurown-300686355.html